NP 500

Drug Profile

NP 500

Alternative Names: NP-500

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Unknown
  • Developer Napo Pharmaceuticals
  • Class Antihyperglycaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Metabolic syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Metabolic-syndrome in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO)
  • 20 May 2008 NP 500 is available for licensing worldwide (http://napopharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top